Browsing Tag
Clearmind Medicine Inc.
3 posts
How Johns Hopkins IRB approval strengthens Clearmind Medicine’s clinical credibility in addiction medicine
Clearmind Medicine’s Johns Hopkins-backed CMND-100 trial expansion could reshape addiction therapeutics. Discover what industry observers are watching next.
How intranasal delivery could reshape Clearmind Medicine Inc.’s MEAI development strategy in addiction
Find out how Clearmind Medicine Inc.’s intranasal MEAI strategy could reshape addiction drug development risk and execution.
Clearmind Medicine files U.S. patent for non-hallucinogenic MEAI therapy targeting cocaine addiction
Find out how Clearmind Medicine’s new U.S. patent filing for its non-hallucinogenic MEAI therapy could transform cocaine addiction treatment and investor sentiment.